

- A²ent
11. (AMENDED) A pharmaceutical composition according to [any one of claims 7 to 10] claim 10 wherein said growth factor is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.
-
- A²
16. (AMENDED) A method according to [any one of claims 13 to 15] claim 13 wherein said soluble receptor is in the form of a receptorbody.
17. (AMENDED) A method according to claim [13 to] 16 wherein said growth factor is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.
-

REMARKS

The subject application is the U.S. National Stage of International Application No. PCT/US97/14536. Claims 1-3 were in the application as filed on 19 August 1997. The claims were amended under Article 34 and claims 1-21 are pending. A copy of pending claims 1-21 is enclosed with the concurrently filed Transmittal Letter Under 35 USC 371. By this Preliminary Amendment, applicants have cancelled claims 18-21 without prejudice and amended claims 4-5, 10-11 and 16-17. Applicants respectfully request entry of this Preliminary Amendment. No issue of new matter is raised by this Amendment. Upon entry of this Amendment, claims 1-17 will be pending and before the Examiner.

No fee, other than the enclosed National Stage Filing Fee is deemed necessary at this time. However, if any additional fee is deemed necessary, the Commissioner is hereby authorized to charge any such additional fee to Deposit Account No. 18-0650.

Respectfully submitted,

By Robert J. Cobert
Gail M. Kempler
Reg. No. 32,143
Robert J. Cobert
Reg. No. 36,108
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

CLAIMS

- (AMENDED)
1. Use of a soluble form of a receptor for a growth factor for the delivery of said growth factor comprising the step of ~~in the manufacture of a medicament for enhancing the~~ ~~coadministering said growth factor with said soluble form of the growth factor receptor such that said growth factor and said soluble form of the~~ ~~intracerebral, extracerebral, intraparenchymal, intracerebraventricular or intrathecal delivery of said~~ ~~growth factor~~ ^{are delivered intracerebrally, extra-cerebrally, intraparenchymally, intracerebraventricularly or intrathecally} ~~by coadministration of said growth factor with said soluble form of the growth factor receptor.~~
 2. Use according to claim 1 wherein the growth factor is a neurotrophin.
 3. Use according to claim 1 wherein the growth factor is Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin 3 (NT-3), Neurotrophin- 4/5 (NT-4/5), Ciliary Neurotrophic Factor (CNTF) or Glial-Derived Neurotrophic Factor (GDNF).
 4. Use according to any one of the preceding claims wherein said soluble receptor is in the form of a receptorbody.
 5. Use according to any one of the preceding claims wherein said growth factor is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.
- (AMENDED)
6. Use according to claim 5 wherein said growth factor is BDNF and the soluble receptor is a TrkB¹gG receptorbody.
 7. A pharmaceutical composition comprising a growth factor; a soluble form of a receptor for said growth factor; and a pharmaceutically acceptable vehicle.
 8. A pharmaceutical composition according to claim 7 wherein the growth factor is a neurotrophin.
 9. A pharmaceutical composition according to claim 7 wherein the growth factor is Nerve Growth Factor (NGF), Brain-

MARKED-UP VERSION

-29-

Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5), Ciliary Neurotrophic Factor (CNTF) or Glial-Derived Neurotrophic Factor (GDNF).

10. A pharmaceutical composition according to any one of claims 7 to 9 wherein said soluble receptor is in the form of a receptorbody.
11. A pharmaceutical composition according to any one of claims 7 to 10 said growth factor is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.
12. (Amended)
A pharmaceutical composition according to claim 11 wherein said growth factor is BDNF and the soluble receptor is a TrkB-IgG receptorbody.
13. A method for enhancing the intracerebral, extracerebral, intraparenchymal, intracerebraventricular or intrathecal delivery of a growth factor by coadministration of said growth factor with said soluble form of the growth factor receptor.
14. A method according to claim 13 wherein the growth factor is a neurotrophin.
15. A method according to claim 13 wherein the growth factor is Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5), Ciliary Neurotrophic Factor (CNTF) or Glial-Derived Neurotrophic Factor (GDNF).
16. A method according to any one of claims 13 to 15 wherein said soluble receptor is in the form of a receptorbody.
17. A method according to claim 13 to 16 said growth factor

AMENDED SHEET

MARKED-UP VERSION

-30-

is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.

- (Amended)
18. A method according to claim 17 wherein said growth factor is BDNF and the soluble receptor is a TrkB-IgG receptorbody.
 19. Use according to claim 1 substantially as hereinbefore described.
 20. A pharmaceutical composition according to claim 7 substantially as hereinbefore described.
 21. A method according to claim 13 substantially as hereinbefore described.

AMENDED SHEET